Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase II, Single-arm Study Evaluating the Efficacy and Safety of Pamiparib in Consolidation Therapy for Limited-stage Small Cell Lung Cancer That Has Not Progressed After Concurrent Chemoradiotherapy

NCT05483543 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05483543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05483543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase II, Single-arm Study Evaluating the Efficacy and Safety of Pamiparib in Consolidation Therapy for Limited-stage Small Cell Lung Cancer That Has Not Progressed After Concurrent Chemoradiotherapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2022
Completion date
December 31, 2024
Enrollment
44 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage small cell lung cancer